Clinical Trial

Engineered Immune Effectors Against Cervical Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-11-29; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT03362619
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Cervical Cancer
Enrollment 20 participants
Start Date 2026-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23